Quarry LP’s Candel Therapeutics CADL Stock Holding History

Quarry LP’s Portfolio CADL Stock Details CADL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,200	Closed	-$21.4K	–	2187
2025 Q3	$21.4K	Buy	+4,200	New	+$24.3K	﹤0.01%	1360

Other funds holding CADL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HFF

Halter Ferguson Financial Carmel, Indiana $456M AUM 49.85% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Quarry LP's CADL Position: Q4 2025 in Review

Quarry LP sold out of Candel Therapeutics (CADL) in Q4 2025, closing a stake of 4,200 shares — an estimated $21.4K sold.

Quarry LP first reported a position in CADL in Q3 2025 and held it in 1 quarter. The position peaked at $21.4K in Q3 2025. 84 funds tracked by Wall St. Rank hold CADL as of Q4 2025.

Quarry LP reported no remaining Candel Therapeutics position as of Q4 2025 after selling out during the quarter.
Quarry LP sold 4,200 Candel Therapeutics shares in Q4 2025, an estimated $21.4K.
Quarry LP first reported a position in Candel Therapeutics in Q3 2025 and held it in 1 quarter.
Quarry LP's Candel Therapeutics position peaked at $21.4K in Q3 2025.
84 funds tracked by Wall St. Rank held Candel Therapeutics as of Q4 2025.

Based on Quarry LP's 13F filing for Q4 2025, filed 13 Feb 2026.